Company / R&D Expense
Intellia Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$388.9M
FY2025
5-year range
$108.4M / $466.3M
FY2021-FY2025
Trend
-16.6%
vs FY2024
Sector context
#20 of 110
Health Care
What the data says
Intellia Therapeutics, Inc.'s r&d expense of $389M is higher than 82% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 10 years, ranging from $32M in FY2018 to $466M in FY2024.
Based on SEC 10-K filings.
$389M in FY2025 with a 5-year CAGR of +20.9%. Top quartile in the Health Care sector.
Declined from $435M to $389M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +37.2%
- 5-Year CAGR
- +20.9%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 110This company $388.9M Sector average $298.2M
▼
+30.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +20.9%, indicating consistent growth.
- In FY2025, r&d expense decreased 16.6% year-over-year.
- Ranks #20 out of 110 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $388.9M | -16.6% |
| FY2024 | $466.3M | +7.2% |
| FY2023 | $435.1M | +189.3% |
| FY2022 | $150.4M | +38.7% |
| FY2021 | $108.4M | -27.9% |
| FY2020 | $150.4M | +122.3% |
| FY2019 | $67.6M | +112.5% |
| FY2018 | $31.8M | -52.9% |
| FY2017 | $67.6M | +112.5% |
| FY2016 | $31.8M | +185.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026